Comparison of 2 type of neoadjuvant chemotherpy in breast cancer
- Conditions
- Breast cancer.Malignant neoplasm of breastc50-c50
- Registration Number
- IRCT2014051117644N1
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
A) positive pathology of breast cancer; Karnofsky performance status at least: 70; locally advanced breast cancer; age< 65 Years old; normal cardiac and liver and bone marrow function; normal and acceptable cardiac evaluation in high risk patients or past medical history of cardiac problem; filling the informed consent by patient.
B) Exclusion criteria: receiving previous chemotherapy for breast cancer; clinical or pathological positive evidence of metastasis; underling disease which can’t receive chemotherapy; known contraindication for chemotherapy agent (taxan reaction); sever cardiac problem history such as heart failure, chest pain which needs medication, sever cardiac valve disease, myocardial infarction, uncontrolled blood pressure (systolic pressure above 180 mm/Hg and diastolic pressure above 100 mm/Hg); refusing treatment by patient.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response. Timepoint: Befor treatment start and every 3 weeks for 4 cycle after treatment. Method of measurement: Caliper measurment (milimeter).;Radiologic response. Timepoint: Befor treatment and 3month after chemotherapy. Method of measurement: Sonography.;Pathologic response. Timepoint: 3 months later after chemotherapy followed by surgery. Method of measurement: Pathologic size (milimeter).
- Secondary Outcome Measures
Name Time Method Bone marrow suppression. Timepoint: Befor chemotherpy and every 3 weeks after chemotherapy. Method of measurement: Lab data.;Extrimity edema. Timepoint: Befor chemotherpy and every 3 weeks after chemotherapy. Method of measurement: History and physical exam.;Alopecia. Timepoint: Befor chemotherpy and every 3 weeks after chemotherapy. Method of measurement: History and exam.